Partnership introduces bioactives to global beauty and personal care markets Berkeley, CA – Demetrix and German global specialty chemicals company Evonik, announce a supply agreement for cannabinoids to be used in…
Demetrix has initiated its 2022 commercial manufacturing campaign to support sales of cannabigerol (CBG). Initial global customers in the personal care and nutrition segments have agreed to purchase approximately 70% of our total production this year.
Biotechnology company signs CMO to produce metric tons of rare cannabinoids for nutraceutical, skincare, and other consumer health and wellness products. BERKELEY, Calif. – February 23, 2021 – Demetrix, Inc.,…
Biotechnology company using fermentation to create rare cannabinoids begins delivering samples up to tens of grams, allowing skincare and consumer products companies to begin formulation work BERKELEY, Calif – November…
Biotechnology company focused on using fermentation to produce cannabinoids for safe, legal, and effective consumer products and pharmaceuticals scales to 15,000-liter production runs of CBG BERKELEY, Calif – September 3,…
Demetrix secures $50 million in Series A funding to provide cannabinoids to pharmaceutical, supplement, and consumer product companies. Funding Round led by Tuatara Capital with Continued Participation by Horizons Ventures…